<DOC>
	<DOCNO>NCT01839396</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Boston Scientific 's Vercise Deep Brain Stimulation ( DBS ) system treatment patient advance , levodopa-responsive bilateral Parkinson 's disease ( PD ) adequately control medication .</brief_summary>
	<brief_title>Deep Brain Stimulation ( DBS ) Treatment Parkinson 's Disease</brief_title>
	<detailed_description>The study multi-center , prospective , double-blind , randomize ( 3:1 ) control trial .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Key Diagnosis bilateral idiopathic PD ( H &amp; Y ≥ 2 ) duration PD ≥ 5 year . Persistent disable Parkinson 's disease symptom drug side effect ( e.g. , dyskinesia , motor fluctuation , disable `` '' period ) despite optimal medical therapy . Able understand study requirement treatment procedure provide write informed consent studyspecific test procedure perform . Key Any intracranial abnormality medical condition would contraindicate DBS surgery . Have significant psychiatric condition likely compromise subject 's ability comply requirement study protocol Any active implanted device include neurostimulators /or drug delivery pump Any previous thalamotomy , pallidotomy subject undergone DBS procedure . Have significant medical condition likely interfere study procedure likely confound evaluation study endpoint . A female breastfeeding childbearing potential positive urine pregnancy test use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Intrepid , Vercise , PD , DBS , Boston Scientific</keyword>
</DOC>